Difference between revisions of "Fannin Innovation Studio"

From edegan.com
Jump to navigation Jump to search
Line 10: Line 10:
 
==Portfolio==
 
==Portfolio==
 
*Accelerox
 
*Accelerox
 +
**ACELEROX is developing novel antioxidant nanoparticles that serve as therapies for reactive oxygen species (ROS)-mediated disease. ROS has been implicated in the progression of a broad range of diseases, including rheumatoid arthritis, multiple sclerosis, ischemic stroke and traumatic brain injury. The company’s proprietary class of molecules, termed PEG-HCCs, can be used to directly treat the symptoms of these diseases as well as to deliver chemotherapeutic drugs into tumors.
 
*ACF Pharmaceuticals
 
*ACF Pharmaceuticals
 +
**
 
*Apaxis Medical
 
*Apaxis Medical
 
*Brevitest Technologies
 
*Brevitest Technologies

Revision as of 13:02, 12 July 2016


Contact

3900 Essex Lane, Suite 575 Houston, Texas 77027

Program

All companies in the Fannin portfolio are medical technology companies in the Texas Medical Center. Fannin Innovation Studio invests in these companies and works with them to take their ideas to market. In exchange for equity, the leaders of Fannin help co-found and manage the companies, and provide companies with working space, networking resources, and investment money. One of the three members of the leadership team manages each portfolio company. Fannin helps its portfolio companies gain grant money, secure licensing, seek mentorship, and move into the next stage of development. [1]

Portfolio

  • Accelerox
    • ACELEROX is developing novel antioxidant nanoparticles that serve as therapies for reactive oxygen species (ROS)-mediated disease. ROS has been implicated in the progression of a broad range of diseases, including rheumatoid arthritis, multiple sclerosis, ischemic stroke and traumatic brain injury. The company’s proprietary class of molecules, termed PEG-HCCs, can be used to directly treat the symptoms of these diseases as well as to deliver chemotherapeutic drugs into tumors.
  • ACF Pharmaceuticals
  • Apaxis Medical
  • Brevitest Technologies
  • Clearview App
  • Guidabot
  • NewHeart
  • Procyrion
    • VC funding
  • Pulmotect

Leadership Team

  • Leo Linbeck III: Chairman and Founder, CEO of Aquinas Companies, LLC
  • Dr. Atul Varadhachary, MD, PhD: Managing Partner
  • Mark Worscheh: CFO, Executive VP of Aquinas Companies, LLC